Truffle Capital, an investor in Wittycell, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors
-
Wittycell, set up in 2005 as a spin-off from the French Institut Jean Godinot, is a biotechnology company developing novel therapeutic and prophylactic vaccine adjuvants in the field of oncology and infectious diseases.
The vaccine market is estimated at over $18 billion.
Wittycell’s potential applications encompass more than 90% of the market. -
The Company develops novel lipid adjuvant products exclusively licensed from and developed in collaboration with three world renowned academic institutions, the Scripps Research Institute (California), the University of Chicago and the Brigham Young University (Utah).
-
Following a €1 million investment by Truffle Capital, Wittycell is aiming to establish proof of concept in animal models on its novel adjuvants and to sell the company to one of the leading vaccine companies.
-
Truffle Venture board member: Philippe Pouletty, M.D.